HK1178444A1 - 呈可溶和結晶形式的長效胰島素類似物製劑 - Google Patents

呈可溶和結晶形式的長效胰島素類似物製劑

Info

Publication number
HK1178444A1
HK1178444A1 HK13105402.6A HK13105402A HK1178444A1 HK 1178444 A1 HK1178444 A1 HK 1178444A1 HK 13105402 A HK13105402 A HK 13105402A HK 1178444 A1 HK1178444 A1 HK 1178444A1
Authority
HK
Hong Kong
Prior art keywords
soluble
long
crystalline forms
acting insulin
insulin analogue
Prior art date
Application number
HK13105402.6A
Other languages
English (en)
Inventor
Michael Weiss
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of HK1178444A1 publication Critical patent/HK1178444A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
HK13105402.6A 2010-02-22 2013-05-06 呈可溶和結晶形式的長效胰島素類似物製劑 HK1178444A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30672210P 2010-02-22 2010-02-22
PCT/US2011/025730 WO2011103575A1 (en) 2010-02-22 2011-02-22 Long-acting insulin analogue preparations in soluble and crystalline forms

Publications (1)

Publication Number Publication Date
HK1178444A1 true HK1178444A1 (zh) 2013-09-13

Family

ID=44483357

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105402.6A HK1178444A1 (zh) 2010-02-22 2013-05-06 呈可溶和結晶形式的長效胰島素類似物製劑

Country Status (14)

Country Link
US (2) US20130085101A1 (zh)
EP (1) EP2538966A4 (zh)
JP (1) JP2013520175A (zh)
KR (1) KR20130043085A (zh)
CN (1) CN102770153B (zh)
AU (1) AU2011217761A1 (zh)
BR (1) BR112012020481A2 (zh)
CA (1) CA2790495A1 (zh)
EA (1) EA201201164A1 (zh)
HK (1) HK1178444A1 (zh)
MX (1) MX2012009618A (zh)
SG (1) SG183106A1 (zh)
WO (1) WO2011103575A1 (zh)
ZA (1) ZA201205315B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
SG181527A1 (en) 2009-12-11 2012-07-30 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9624287B2 (en) * 2012-07-17 2017-04-18 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
CA2907848A1 (en) 2013-04-03 2014-10-09 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
EP3094343A4 (en) 2014-01-13 2017-10-18 Thermalin Diabetes, LLC Rapid action insulin formulations and pharmaceutical delivery systems
WO2016001862A1 (en) * 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
AU2015328222B9 (en) 2014-10-06 2020-12-24 Case Western Reserve University Biphasic single-chain insulin analogues
CA2964918A1 (en) * 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
EP3781147A4 (en) * 2018-04-16 2022-04-20 University of Utah Research Foundation GLUCOSE-SENSITIVE INSULIN
US20210371489A1 (en) * 2018-09-21 2021-12-02 Case Western Reserve University Site 2 single-chain insulin analogues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
ES2554773T3 (es) * 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2009129250A2 (en) * 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability

Also Published As

Publication number Publication date
SG183106A1 (en) 2012-09-27
EA201201164A1 (ru) 2013-04-30
CA2790495A1 (en) 2011-08-25
KR20130043085A (ko) 2013-04-29
AU2011217761A1 (en) 2012-08-02
US20170360895A1 (en) 2017-12-21
EP2538966A4 (en) 2014-02-19
CN102770153B (zh) 2014-05-07
US20130085101A1 (en) 2013-04-04
BR112012020481A2 (pt) 2017-01-10
CN102770153A (zh) 2012-11-07
JP2013520175A (ja) 2013-06-06
MX2012009618A (es) 2013-02-26
WO2011103575A1 (en) 2011-08-25
ZA201205315B (en) 2013-09-25
EP2538966A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
HK1178444A1 (zh) 呈可溶和結晶形式的長效胰島素類似物製劑
HUS1900017I1 (hu) Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk
HUS1700027I1 (hu) Inzulint, nikotinamidot és arginint tartalmazó készítmény
HK1201152A1 (zh) 皮膚遞送組合物和方法
HK1248592A1 (zh) 長效胰島素製劑
PL2558306T3 (pl) Wzory wtryskiwane cyfrowo w powierzchnie proszkowe
HK1224147A1 (zh) 供給營養素的製劑和方法
EP2536293A4 (en) METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE
ZA201404417B (en) Human insulin analogue and acylated derivative thereof
SG11201401835VA (en) Ultra-concentrated rapid-acting insulin analogue formulations
EP2593033C0 (en) Dental implant and dental abutment intended to be connected to this dental implant
EP2700654A4 (en) HUMAN INSULIN AND ANALOG CONJUGATE THEREOF
EP2894163A4 (en) GLP-1 ANALOG, PREPARATION METHODS AND USE THEREOF
HK1201264A1 (zh) 長效的可注射的莫昔克丁配製劑和新的莫昔克丁晶型
GB201110769D0 (en) Improvements in and relating to cut/copy and paste functionality
GB201004936D0 (en) Improvements in and relating to furniture
PL2441433T3 (pl) Olleya marilimosa i ich zastosowanie w sposobie wytwarzania kompozycji zawierającej zeaksantynę
ZA201206667B (en) Improvements in and relating to implements
GB2480250B (en) Improvements in and relating to transporters
HK1169392A1 (zh) 製備 -乙酰基異喹啉及其衍生物的方法
GB201001417D0 (en) Improvements in and relating to stabilisation systems
GB201021105D0 (en) Improvements in and relating to parathas
GB201004608D0 (en) Improvements in and to processes

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180222